Temazepam 10mg Tablets

VIP Member

You need to be a VIP to buy this product. Read all about our VIP program here.

Temazepam (sold under the brand names Restoril among others) is a medication used to treat insomnia. Such use should generally be for less than ten days. It is taken by mouth. Effects generally begin within an hour and last for up to eight hours.

Common side effects include sleepiness, anxiety, confusion, and dizziness. Serious side effects may include hallucinations, abuse, and anaphylaxis. Use is generally not recommended together with opioids. If the dose is rapidly decreased withdrawal may occur. Use during pregnancy or breastfeeding is not recommended. Temazepam is an intermediate acting benzodiazepine and hypnotic. It works by affecting GABA within the brain.

Temazepam was patented in 1962 and came into medical use in 1969. It is available as a generic medication. In 2017, it was the 142nd most commonly prescribed medication in the United States, with more than four million prescriptions.

Email me when back in stock

SKU: TEMAZEPAM_10MG_TABLET Category: Tags: , , , , , ,

Temazepam (trade name Restoril) is a intermediate-acting psychoactive substance of the benzodiazepine class, which produces anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsant, and amnesic effects.

Temazepam, like other benzodiazepines, binds to specific sites on the GABAA gamma-amino-butyric acid receptor. Temazepam is commonly used for the short term treatment of insomnia and as a preoperative sedative. Temazepam has a rapid onset of action and symptomatic relief. The hypnotic effects take between 20-90 minutes to take effect. Temazepam is effective for both inducing sleep and maintaining sleep.

It’s worth noting the sudden discontinuation of benzodiazepines can be potentially dangerous or life-threatening for individuals using regularly for extended periods, sometimes resulting in seizures or death. It is highly recommended tapering one’s dose by gradually lowering the amount taken each day for a prolonged period of time, instead of stopping abruptly.

Temazepam is a drug of the benzodiazepine class. Benzodiazepine drugs contain a benzene ring fused to a diazepine ring, which is a seven membered ring with the two nitrogen constituents located at R1 and R4. The benzyl ring of temazepam is substituted at R8 with a chlorine group. Further, the diazepine ring is bonded at R5 to a phenyl ring. Temazepam also has a hydroxyl group bonded to the 3-position of the diazepine ring.

Temazepam is a white, crystalline substance, slightly soluble in water, and sparingly soluble in alcohol.

Benzodiazepines produce various effects by binding to the benzodiazepine receptor site, magnifying the efficiency and effects of the neurotransmitter gamma aminobutyric acid (GABA) by acting on its receptors. As this site is the most prolific inhibitory receptor set within the brain, its modulation results in the sedating (or calming effects) of temazepam on the nervous system. When temazepam binds to the GABAA receptor, it causes the Cl-ion pore to open more frequently. The anticonvulsant properties of benzodiazepines may be, in part or entirely, due to binding to voltage-dependent sodium channels, rather than benzodiazepine receptors.

Its main pharmacological action is to increase the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor. This causes sedation, motor impairment, ataxia, anxiolysis, an anticonvulsant effect, muscle relaxation, and a reinforcing effect. As a medication before surgery, temazepam decreased cortisol in elderly patients. In rats, it triggered the release of vasopressin into the periventricular nucleus of the hypothalamus, and decreased the release of ACTH under stress.

In a single- and multiple-dose absorption, distribution, metabolism, and excretion (ADME) study, using tritium-labeled drug, temazepam was well absorbed and found to have minimal (8%) first-pass drug metabolism. No active metabolites were formed, and the only significant metabolite present in blood was the O-conjugate. The unchanged drug was 96% bound to plasma proteins. The blood-level decline of the parent drug was biphasic, with the short half-life ranging from 0.4-0.6 hours and the terminal half-life from 3.5–18.4 hours (mean 8.8 hours), depending on the study population and method of determination.



CAS Number

Chemical class

InChi Key

IUPAC name

Price is per

Psychoactive class



Customer Reviews

No reviews yet
Shopping Cart
Scroll to Top